# EDGAR Filing Document

**Accession Number:** 0001824293
**File Stem:** 0001824293-23-000011
**Filing Date:** 2023-1
**Character Count:** 14518
**Document Hash:** 0f2272504d95e8229e13f3eeb05bcab0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001824293-23-000011.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001824293-23-000011

**CONFORMED SUBMISSION TYPE**: 425

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vallon Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001824293
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 824369909
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 425
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40034
- **FILM NUMBER:** 23522596

**BUSINESS ADDRESS:**
- **STREET 1:** TWO LOGAN SQUARE
- **STREET 2:** 100 N. 18TH STREET, SUITE 300
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103
- **BUSINESS PHONE:** (267) 607-8255

**MAIL ADDRESS:**
- **STREET 1:** TWO LOGAN SQUARE
- **STREET 2:** 100 N. 18TH STREET, SUITE 300
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vallon Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001824293
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 824369909
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 425

**BUSINESS ADDRESS:**
- **STREET 1:** TWO LOGAN SQUARE
- **STREET 2:** 100 N. 18TH STREET, SUITE 300
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103
- **BUSINESS PHONE:** (267) 607-8255

**MAIL ADDRESS:**
- **STREET 1:** TWO LOGAN SQUARE
- **STREET 2:** 100 N. 18TH STREET, SUITE 300
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103

![image_0.jpg](image_0.jpg)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549 FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 11, 2023

![image_8.jpg](image_8.jpg)

![logo_filings1.jpg](logo_filings1.jpg)

**VALLON PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40034** | **82-4369909** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) |
| of incorporation) | | |

---

**100 N. 18th Street, Suite 300**

**Philadelphia, PA 19103**

(Address of principal executive offices and zip code)

**(267) 607-8255**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

![image_8.jpg](image_8.jpg)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, par value $0.0001 per share | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VLON | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

![image_0.jpg](image_0.jpg)

![image_8.jpg](image_8.jpg)

------

**Item 8.01 Other Events.**

On January 11, 2023, Vallon Pharmaceuticals, Inc. (the "Company") issued a press release announcing its participation in the Virtual Investor 2023 Companies to Watch Event to be held on January 17, 2023. A copy of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press Release issued by Vallon Pharmaceuticals, Inc., dated January 11, 2023.](ex991_virtualinvestorevent.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: January 11, 2023 | **VALLON PHARMACEUTICALS, INC.** |
|  | By: /s/ Leanne Kelly |
|  | Leanne Kelly |
|  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![image_0.jpg](image_0.jpg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;![gri.jpg](gri.jpg)

**Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event**

*Live video webcast on Tuesday, January 17, 2023 at 1:00 PM ET*

**PHILADELPHIA, PA and LA JOLLA, CA,** January 11, 2023 – Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), ("Vallon" or the "Company"), and GRI Bio, Inc. ("GRI Bio"), a privately held biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that David Baker, President & Chief Executive Officer of Vallon and Marc Hertz, Chief Executive Officer of GRI Bio, will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 1:00 PM ET.

As part of the presentation, Vallon and GRI Bio will discuss their previously announced definitive agreement (the "Merger Agreement") pursuant to which GRI Bio will merge with a wholly-owned subsidiary of Vallon in an all-stock transaction (the "Merger"). The combined company will focus on advancing GRI Bio's innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases. The transaction is expected to close in the first quarter of 2023.

A live video webcast of the presentation will be available on the Events pages of the Investors section of the Company's website (www.vallon-pharma.com).

**About Vallon Pharmaceuticals, Inc.**

Vallon is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company has been focused on the development of new medications to help patients with CNS disorders.

For more information about the Company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter.

References to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.

**About GRI Bio, Inc.**

GRI Bio is a clinical stage biotechnology company focused on fundamentally changing the way inflammatory disease is treated. GRI Bio's NKT cell targeted therapies are being developed for IPF and other fibrotic, inflammatory, and autoimmune diseases. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. NKT I cells play a critical role in initiating and propagating the inflammatory response, injury and fibrosis observed in IPF and other fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of NKT I cell activity and is being developed as a novel oral therapeutic for IPF.

------

**No Offer or Solicitation**

This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of the U.S. Securities Act of 1933, as amended.

**Additional Information About the Proposed Transaction for Investors and Shareholders**

In connection with the Merger, on December 23, 2022, the Company filed with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (No. 333-268977), which included a preliminary proxy statement/prospectus and certain other related documents and intends to file with the SEC any amendments to the registration statement on Form S-4, as required by the SEC (collectively, the "Registration Statement"), which will include a definitive proxy statement/prospectus and certain other related documents, which will be both the proxy statement to be distributed to holders of the Company's common stock in connection with the Company's solicitation of proxies for the vote by the Company's stockholders with respect to the Merger and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities of the Company to be issued in the Merger. **The Company's stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus included in the Registration Statement and the amendments thereto and the definitive proxy statement/prospectus, as well as other documents filed with the SEC in connection with the proposed Merger, as these materials will contain important information about the parties to the Merger Agreement, the Company and the proposed Merger.** After the Registration Statement is declared effective, the definitive proxy statement/prospectus and other relevant materials for the proposed Merger will be mailed to stockholders of the Company as of a record date to be established for voting on the proposed Merger and other matters as may be described in the Registration Statement. Stockholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC's web site at www.sec.gov. In addition, the documents filed by Vallon may be obtained free of charge from Vallon's website at www.vallon-pharma.com or by written request to Vallon at vallon@jtcir.com.

**Participants in the Solicitation**

Vallon, GRI Bio and certain of their respective directors and executive officers may be deemed, under the SEC rules, to be participants in the solicitation of proxies from Vallon stockholders with respect to the matters relating to the Merger. Information regarding Vallon's executive officers and directors is available in Vallon's proxy statement on Schedule 14A for its 2022 annual meeting of stockholders, filed with the SEC on April 27, 2022 and Vallon's Annual Report on Form 10-K for the year-ended December 31, 2022. These documents are available free of charge at the SEC's website at www.sec.gov or by going to Vallon's investor page on its corporate website at www.vallon-pharma.com. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction, and a description of their direct and indirect interests

------

in the proposed transaction, which may differ from the interests of Vallon's stockholders generally, will be set forth in the Registration Statement, when available.

**Forward Looking Statements**

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions. These forward-looking statements are based on Vallon's and GRI Bio's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the timing of the completion of the Merger. Actual results may differ from the expectations, estimates and projections expressed by Vallon and GRI Bio herein and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the ability of Vallon and GRI Bio to meet the closing conditions in the Merger Agreement, including due to failure to obtain approval of the stockholders of Vallon and GRI Bio or certain regulatory approvals, or failure to satisfy other conditions to closing in the Merger Agreement; (2) the occurrence of any event, change or other circumstances, including the outcome of any legal proceedings that may be instituted against Vallon or GRI Bio following the announcement of the Merger Agreement and the transactions contemplated therein, that could give rise to the termination of the Merger Agreement or could otherwise cause the transactions contemplated therein to fail to close; and (3) other risks and uncertainties indicated from time to time in the Registration Statement, including those under the heading "Risk Factors" in the Registration Statement and in Vallon's other filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

**Investor Contact:**

JTC Team, LLC

Jenene Thomas

(833) 475-8247

vallon@jtcir.com

<br>